Why OncoMed’s Update Could Crater the Stock
OncoMed Pharmaceuticals saw its stock sink early Monday morning following an update from its Phase 2 Alpine study.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 229
Agile Therapeutics Announces Pricing for Secondary Offering
Agile Therapeutics fell in Friday’s session, despite the broad markets taking off, after the company announced the pricing for its secondary offering.
Why Alkermes Top-Line Results Might Not Be as Bad as Once Thought
Alkermes absolutely tanked early Thursday morning on less than favorable preliminary top-line results from the first two of three Phase 3 efficacy studies for ALKS 5461.
Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Has a Zafgen Turnaround Begun?
Despite facing setbacks recently, Zafgen pushed ahead and led the bulls early on Wednesday on news of positive results.
Johnson & Johnson Plans to Cut Roughly 3,000 Jobs in Medical Devices
Johnson & Johnson is looking to save some money over the next few years and as a result it is taking action by restructuring its Medical Devices businesses.
UnitedHealth Impresses Shareholders by Meeting Earnings
UnitedHealth Group released a better-than-expected fourth-quarter earnings report before the markets opened on Tuesday.
4 Top BioPharma Movers of the Past Week
These biotech companies stood out from the rest with big moves over the course of the past week.
The Unusual Merrill Lynch Upgrade of Gilead Sciences
Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above water this year.
Why Sarepta Therapeutics Is Cratering
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
Major Pharma Short Sellers Increase Bets
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
Short Interest Remains Mixed for Major Biotechs
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Halozyme Therapeutics Sinks on Business Update
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Celgene Disappoints Investors by Meeting Estimates
Celgene Corp. (NASDAQ: CELG) sank in Monday's session after providing a business update that was largely in line with analyst expectations.